<DOC>
	<DOC>NCT01134640</DOC>
	<brief_summary>A post marketing surveillance, prospective study to collect safety information from 250 subjects with epidermal growth factor receptor (EGFR) expressing, KRAS wild-type metastatic colorectal cancer treated with Erbitux as final evaluable cases.</brief_summary>
	<brief_title>A Post-Marketing Surveillance Study On ErbituxÂ® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>EGFR expressing, KRAS wildtype subjects with metastatic colorectal cancer, who are indicated for Erbitux treatment according to the nationally authorized label (in combination with irinotecan, metastatic colorectal cancer after failure of irinotecanincluding cytotoxic therapy) Subjects who are not eligible for Erbitux treatment according to the indication in national label; or with hypersensitivity reactions (grade 3 or 4) to Erbitux</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>mCRC</keyword>
	<keyword>post marketing surveillance</keyword>
	<keyword>Erbitux</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>KRAS</keyword>
</DOC>